INTERIM REPORT 1 JULY– 30 SEPTEMBER 2019
“We are concluding yet another exciting quarter during which we delivered strong growth in our key European regions, and we added a third commercial leg to our product portfolio. Clinical results were accepted for presentation at several clinical congresses, and we made good progress in the US with our US clinical trial. We also continued to strengthen our IP position during the quarter, which is of utmost importance for us. Our gross order intake grew by 93% in Q3 2019, a strong growth rate. Germany continues to be the market with the most substantial contribution, representing about 80%